SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of sepsis, pulmonary inflammation and fibrosis at the 2025 Respiratory Innovation Summit (RIS) and American Thoracic Society (ATS) International Conference
SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
SignaBlok presented preclinical data on the use of ligand-independent TREM-1 blockers as innate immune checkpoint inhibitors to overcome cancer immunotherapy resistance at the CICON23
SignaBlok awarded NEI / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitors for neovascular retinal diseases
SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new mechanism-based TREM-1 therapy for acute respiratory distress syndrome
SignaBlok’s TREM-1 nanotherapy accepted by the Nanotechnology Characterization Laboratory (NCL, Frederick, Maryland) into its Assay Cascade characterization and testing program as one of the most promising cancer nanomedicine candidates.
SignaBlok awarded NIAMS / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitor for treatment of rheumatoid arthritis
SignaBlok awarded DoD SBIR Phase I contract to support new technology to prevent the effects of acute radiation syndrome
